Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2020
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Cancer - Pipeline Review, H1 2020, provides an overview of the Kidney Cancer (Oncology) pipeline landscape.
Kidney cancer also called renal cancer is a disease in which kidney cells become malignant (cancerous) and grows out of control, forming a tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for weeks, extreme fatigue, and anemia, shortness of breath and bone pain. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Kidney Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Kidney Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 20, 162, 156, 2, 12, 101, 11 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 14, 8, 1, 16 and 1 molecules, respectively.
Kidney Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Kidney Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kidney Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kidney Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kidney Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kidney Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Introduction
Kidney Cancer - Overview
Kidney Cancer - Therapeutics Development
Kidney Cancer - Therapeutics Assessment
Kidney Cancer - Companies Involved in Therapeutics Development
Kidney Cancer - Drug Profiles
Kidney Cancer - Dormant Projects
Kidney Cancer - Discontinued Products
Kidney Cancer - Product Development Milestones
Appendix
Tables and Figures
List of Tables
Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by 4D Pharma Plc, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by 4SC AG, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Aadi Bioscience Inc, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by AbbVie Inc, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by ABL Bio Inc, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Acepodia Biotech Inc, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Acrotech Biopharma LLC, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Actuate Therapeutics Inc, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Adaptimmune Therapeutics Plc, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by ADC Therapeutics SA, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Adlai Nortye Biopharma Co Ltd, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Advenchen Laboratories LLC, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Affimed GmbH, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Affitech A/S, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Agenus Inc, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by AIM ImmunoTech Inc, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Akeso Inc, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Alkermes Plc, H1 2020
Kidney Cancer (Renal Cell Cancer) - Pipeline by Alligator Bioscience AB, H1 2020
Companies Mentioned
4D Pharma Plc
4SC AG
Aadi Bioscience Inc
AbbVie Inc
ABL Bio Inc
Acepodia Biotech Inc
Acrotech Biopharma LLC
Actuate Therapeutics Inc
Adaptimmune Therapeutics Plc
ADC Therapeutics SA
Adlai Nortye Biopharma Co Ltd
Advenchen Laboratories LLC
Affimed GmbH
Affitech A/S
Agenus Inc
AIM ImmunoTech Inc
Akeso Inc
Alkermes Plc
Alligator Bioscience AB
Allogene Therapeutics Inc
Almac Discovery Ltd
AlphaMab Co Ltd
Alphamab Oncology
Altor Bioscience LLC
ALX Oncology Inc
Ambrx Inc
Amgen Inc
Amphivena Therapeutics Inc
Anaveon AG
Andes Biotechnologies
Anew Oncology Inc
Anhui Anke Biotechnology (Group) Co Ltd
Antengene Corp
AntiCancer Inc
Apcure SAS
APEIRON Biologics AG
Apexigen Inc
Apollomics Inc
Apotex Inc
Aprea Therapeutics AB
Aravive Inc
Arcus Biosciences Inc
Argenx SE
Arrowhead Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
Beijing Eastern Biotech Co Ltd
Beijing Foreland Pharma Co Ltd
Beijing Kawin Technology Share-Holding Co Ltd
Benhealth Biopharmaceutical (Shenzhen) Co Ltd
Bio-Path Holdings Inc
Bio-Thera Solutions Ltd
Biocad
Biocon Ltd
Biohaven Pharmaceutical Holding Company Ltd
BioIntegrator Ltd
Bionomics Ltd
BioNTech SE
Biotest AG
BioXpress Therapeutics SA
Boehringer Ingelheim International GmbH
Boryung ViGenCell Inc
Boston Biomedical Inc
BridgeBio Pharma Inc
Bristol-Myers Squibb Co
Byondis BV
Calithera Biosciences Inc
Canget BioTekpharma LLC
CASI Pharmaceuticals Inc
Celldex Therapeutics Inc
Celyad Oncology
Centurion BioPharma Corp
Checkpoint Therapeutics Inc
Chineo Med Beijing Co Ltd
Chipscreen Biosciences Ltd
Cleveland BioLabs Inc
Clovis Oncology Inc
COARE Biotechnology Inc
CoImmune Inc
Constellation Pharmaceuticals Inc
Corvus Pharmaceuticals Inc
CRISPR Therapeutics AG
CSPC Pharmaceutical Group Ltd
CureLab Oncology Inc
Cytocom Inc
Daiichi Sankyo Co Ltd
Debiopharm International SA
DevaCell Inc
Dr. Reddy's Laboratories Ltd
Dragonfly Therapeutics Inc
Ecrins Therapeutics SAS
eFFECTOR Therapeutics Inc
EirGenix Inc
Eisai Co Ltd
Eli Lilly and Co
Ellipses Pharma Ltd
EnGeneIC Ltd
Enochian Biosciences Inc
EpimAb Biotherapeutics Inc
Epizyme Inc
Epygen Biotech Pvt Ltd
Ervaxx Ltd
Esanex Inc
Esperance Pharmaceuticals Inc
Evaxion Biotech ApS
Evelo Biosciences Inc
Exelixis Inc
EXUMA Biotech Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Five Prime Therapeutics Inc
Fresenius SE & Co KGaA
GEMoaB Monoclonals GmbH
Gene Techno Science Co Ltd
Genentech Inc
Geneos Therapeutics Inc
Genmab AS
Genocea Biosciences Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
GLG Pharma SA
Glycotope GmbH
Guangzhou Hanghua Bio Pharmaceutical Technology Co
Handa Pharmaceuticals LLC
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
HEC Pharm Co Ltd
Helixmith Co Ltd
Hengenix Biotech Inc
Hibiskus Biopharma Inc
Horizon Therapeutics Plc
Hualan Biological Engineering Inc
Hutchison MediPharma Ltd
Idera Pharmaceuticals Inc
Ikena Oncology Inc
Immune Pharmaceuticals Inc
Immune System Key Ltd
Immune Therapeutics Inc
ImmuneSensor Therapeutics Inc
Immunicum AB
ImmunityBio Inc
Immunocore Ltd
ImmunoGen Inc
Immunomedics Inc
Immunomet Therapeutics Inc
Incyte Corp
Infinity Pharmaceuticals Inc
Inhibrx Inc
Inmune Bio Inc
Innate Pharma SA
InnoCare Pharma Ltd
Innovative Cellular Therapeutics Co Ltd
Innovent Biologics Inc
InSight Biopharmaceuticals Ltd
InteRNA Technologies BV
IO Biotech ApS
Jiangsu Aosaikang Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Jounce Therapeutics Inc
JSK Therapeutics Inc
Jubilant Therapeutics Inc
Karyopharm Therapeutics Inc
Kinnate Biopharma Inc
Komipharm International Co Ltd
Konruns Pharmaceutical Co Ltd
Kuda Therapeutics Inc
Kymab Ltd
Kyowa Kirin Co Ltd
Lantern Pharma Inc
Lead Discovery Center GmbH
Lipac Oncology LLC
Lotus Pharmaceutical Co Ltd
Luye Pharma Group Ltd
Lycera Corp
MacroGenics Inc
Mana Therapeutics Inc
Mantis Therapeutics BV
Marino Biotechnology Co Ltd
MaxiVAX SA
MdBioLab
MediciNova Inc
MedPacto Inc
Merck & Co Inc
Merck KGaA
Mersana Therapeutics Inc
Metagone Biotech Inc
Metis Precision Medicine
Midissia Therapeutics Inc
Millennium Pharmaceuticals Inc
Mirati Therapeutics Inc
Miyarisan Pharmaceutical Company Ltd
Moderna Inc
Modulation Therapeutics Inc
Molecular Partners AG
Molecular Templates Inc
Moleculin Biotech LLC
Multitude therapeutics Inc
MultiVir Inc
Mycenax Biotech Inc
NanoCarrier Co Ltd
Nanology LLC
NantKwest Inc
Nektar Therapeutics
Neoleukin Therapeutics Inc
NeoTX Therapeutics Ltd
Novartis AG
Ocellaris Pharma Inc
Omeros Corp
OncBioMune Pharmaceuticals Inc
OncoImmune Inc
Oncology Venture A/S
Oncology Venture U.S. Inc
Oncolys BioPharma Inc
Oncopeptides AB
Oncorena AB
Oncovir Inc
Ono Pharmaceutical Co Ltd
Orion Corp
Orpheus Therapeutics Inc
Pact Pharma Inc
Peptron Inc
Pfizer Inc
Pharma Mar SA
PharmAbcine Inc
Pharmicell Co Ltd
Philogen SpA
Phosplatin Therapeutics LLC
Poseida Therapeutics Inc
Prestige BioPharma Pte Ltd
PsiOxus Therapeutics Ltd
QED Therapeutics Inc
Qilu Puget Sound Biotherapeutics Corp
Qu Biologics Inc
Quadriga BioSciences Inc
Qualigen Therapeutics Inc
RAPT Therapeutics Inc
Regeneron Pharmaceuticals Inc
RemeGen Ltd
Replimune Ltd
RevImmune SAS
Rexahn Pharmaceuticals Inc
Richter Gedeon Nyrt
Rizen (Suzhou) Biosciences Co Ltd
Ryvu Therapeutics SA
Samyang Biopharmaceuticals Corp
Sanofi
Sapphire Biotech Inc
Sareum Holdings Plc
Scancell Holdings Plc
Scholar Rock Inc
Schrodinger LLC
Seneca Therapeutics Inc
Seven and Eight Biopharmaceuticals Corp
Shanghai Junshi Bioscience Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shattuck Labs Inc
Shijiazhuang Yiling Pharmaceutical Co Ltd
Shionogi & Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sichuan Huiyang Life Science and Technology Corp
Sichuan Sinovation Bio-technology Co Ltd
SignalRx Pharmaceuticals Inc
Sillajen Biotherapeutics
Sinocelltech Ltd
Sonoval LLC
Sorrento Therapeutics Inc
Sotio AS
Spring Bank Pharmaceuticals Inc
Sprint Bioscience AB
Starpharma Holdings Ltd
Steba Biotech SA
Sumitomo Dainippon Pharma Co Ltd
Suntec Medical (Taiwan) Inc
Surface Oncology Inc
Suzhou Kintor Pharmaceutical Inc
Suzhou Stainwei Biotech Inc
Syndax Pharmaceuticals Inc
Syndivia SAS
Synermore Biologics Co Ltd
T-Cure Bioscience Inc
Tactical Therapeutics Inc
Taiho Oncology Inc
Taiho Pharmaceutical Co Ltd
Tarus Therapeutics Inc
Telix Pharmaceuticals Ltd
Tempest Therapeutics Inc
Teon Therapeutics Inc
TheraPten Biosciences Inc
Torque Therapeutics Inc
Turning Point Therapeutics Inc
TVAX Biomedical Inc
Tyme Technologies Inc
UbiVac LLC
Vaccibody AS
Vault Pharma Inc
Vaxiion Therapeutics Inc
Veana Therapeutics LLC
Vyriad Inc
X4 Pharmaceuticals Inc
Xbrane Biopharma AB
Xcovery Holding Co LLC
Xencor Inc
Xspray Pharma AB
Xynomic Pharmaceuticals Holdings Inc
Y-mAbs Therapeutics Inc
Yuhan Corp
Zelluna Immunotherapy AS
Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets